Mizuho Securities analyst Mara Goldstein maintained a Buy rating on TCR2 Therapeutics (TCRR – Research Report) today and set a price target of $20.00. The company’s shares closed today at $1.09.
According to TipRanks, Goldstein is an analyst with an average return of -4.0% and a 31.19% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Nektar Therapeutics, and Merck & Company.
TCR2 Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $9.40, representing a 762.39% upside. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $10.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $4.30 and a one-year low of $0.82. Currently, TCR2 Therapeutics has an average volume of 290.4K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
TCR2 Therapeutics, Inc. is an immunotherapy company, which develops biological drugs and engineering T-cells for cancer therapy. The company offers cancer therapy, T-cell biology, Immunology and Molecular biology. It also engages in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded in May 2015 and is headquartered in Cambridge, MA.
Read More on TCRR:
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TCR² Therapeutics Announces Pipeline Priorities for 2023
- TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
- TCR2 Therapeutics price target lowered to $8 from $16 at Piper Sandler
